In the present study, 32 patients (32%) met the criteria of low Alb (Alb < 3.3 g/dL) and high CRP (CRP > 1.9 mg/dL) levels, and approximately half of them experienced cancer-related death within 3 months of starting treatment, with 70% succumbing to cancer within 7 months (Fig. 4). Here, ALB is linked to cancer.